The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

Share Price Information for Biome Tech (BIOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 100.00
Bid: 90.00
Ask: 110.00
Change: 0.00 (0.00%)
Spread: 20.00 (22.222%)
Open: 100.00
High: 100.00
Low: 100.00
Prev. Close: 100.00
BIOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

22 Sep 2022 07:00

RNS Number : 2206A
Biome Technologies PLC
22 September 2022
 

This announcement contains inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.

 

22 September 2022

Biome Technologies plc

("Biome", "the Company" or "the Group")

Interim Results

 

Biome Technologies plc announces its unaudited Interim Results for the six months ended 30 June 2022.

 

Highlights

· The Group generated revenues of £2.4m (H1 2021: £2.6m) and gross profit of £0.9m (H1 2021: £0.9m)

· The Biome Bioplastics division was the principal revenue generator for the Group. However, raw material availability limited revenues achieved in H1

· New customers for Biome Bioplastics, gained in the last few years in both North America and Europe, grew three-fold in terms of revenue contribution in the period and now count for 32% of revenues (H1 2021: 10%)

· Anticipated H2 2022 revenues from Biome Bioplastics' increased supply of biodegradable coffee filter material to a second large US customer are now expected to be significantly lower than previously anticipated, impacting expected revenues from this customer in 2022 and 2023

· Biome Bioplastics is also experiencing other customer launch delays related to raw material supply, logistics and uncertainty of end-consumer behaviour in the current economic climate, all of which have and will have an impact on the revenue generation of this division

· The Stanelco RF Technologies division is working to deliver the major contracts announced previously. Elongated lead-times for critical components, particularly electronics, have delayed some shipments. However, key issues have been resolved and these shipments have or are expected to occur in H2 2022 with revenues from this division in the second half expected to be above previous Board expectations

· The Board now believes that Group revenues for the years ending 31 December 2022 and 2023 will be substantially below current market expectations with a consequential substantial impact on the Group's loss/profit before interest, taxation, depreciation, amortisation and share option charges in those years

· Despite trading conditions deteriorating significantly, the Board believes the Group has sufficient working capital for the foreseeable future

· Accounts receivable financing agreement signed in August 2022 provides new working capital finance of up to £600k as required

 

ul Mines, Chief Executive Officer said:

"Growth has been limited in both divisions in the first half by ongoing supply challenges. The trading environment for Biome Bioplastics is becoming more difficult with a number of factors impacting our revenue expectations for this year and 2023. We continue to work with our customers on new products that we believe will unlock more value and I am particularly encouraged by the diversification of our customer base and applications in both divisions."

 

 

For further information please contact:

Biome Technologies plc

Paul Mines, Chief Executive Officer

Rob Smith, Chief Financial Officer

Tel: +44 (0) 2380 867 100

info@biometechnologiesplc.co.uk

Allenby Capital

David Hart/Alex Brearley (Nominated Adviser)

Kelly Gardiner (Sales and Corporate Broking)

Tel: +44 (0) 20 3328 5656

 

 

About Biome

Biome Technologies plc (Ticker: BIOM) is an AIM listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where value-added pricing can be justified and that are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

 

The Group comprises two divisions, Biome Bioplastics Limited and Stanelco RF Technologies Limited. Biome Bioplastics is a leading developer of highly functional, bio-based and biodegradable plastics. The company's mission is to produce bioplastics that challenge the dominance of oil-based polymers. Stanelco RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics markets.

 

www.biometechnologiesplc.com www.biomebioplastics.com and www.thinkbioplastic.com www.stanelcorftechnologies.com

 

 

Chairman's Statement

 

As mentioned in our last trading update, the Group's two divisions were challenged by supply constraints in the global economy during the first half of 2022. For the Biome Bioplastics Division ("Bioplastics") the realisation of ambition was limited by the challenges of procuring raw materials in a timely manner and by end-customers struggling with their own production schedules. For Stanelco RF Technologies Division ("RF Technologies") the problems related to sourcing specific electronic components and sub-assemblies, which limited revenues despite a good order book backlog. The net result was Group revenues for the period of £2.4m, slightly behind the previous half year (H1 2021: £2.6m).

 

Gross profit for the Group was £0.9m (H1 2021: £0.9m) on the back of improved margins and mix of sales. Other income, in the form of grant receipts in support of the Group's work on novel bioplastics, was £0.2m (H1 2021: £0.1m). The overall gross margin for the Group rose to 36% (H1 2021: 33%) reflecting an improved mix of product sales and tight controls on purchase pricing in both divisions.

 

Despite the context of inflationary pressures, administrative expenses continued to be tightly controlled in the period and were in line with the first half of 2021 at £1.7m (H1 2021: £1.7m). The Group recorded a loss before interest, depreciation, amortisation and share option charges for the six months to 30 June 2022 of £0.4m (H1 2021: £0.5m loss)1. The loss after taxation was £0.6m (H1 2021: £0.7m loss), which equates to a loss per share of 17 pence on both a basic and diluted basis (H1 2021: loss per share of 19 pence on a basic and diluted basis).

 

The Group's cash position as at 30 June 2022 was £0.7m (31 December 2021: £1.0m) reflecting the first half's losses. As at 30 June 2022, the Group continued to have no external bank borrowings. Post period end, we were pleased to announce that the Group has entered into a receivables financing agreement with Accelerated Payments Limited.

 

Revenues in Bioplastics for the period fell just short of internal expectations as the late delivery of raw materials to one of the North American manufacturing sites limited the realisation of some revenues towards the end of the second quarter. Sales for H1 2022 of £2.0m (H1 2021: £2.3m) represented a decrease of 10.6% when compared to the corresponding period in the prior year.

 

We are seeing some easing of the logistics issues that have limited the business in the last 18 months albeit our customers are experiencing volatility in their own production schedules and are struggling to launch new products on defined timescales into markets in which there is considerable demand and pricing variability.

 

The revenue performance in the period remained underpinned by a continuance of sales to existing customers for outer packaging for the US coffee market, albeit limited by supply chain issues and stocking reductions. However, of note is that revenues to new customers in both North America and Europe grew three-fold in the period and now represent 32% of revenues (H1 2021: 10%). A number of these new customers are in the packaging film area where the Company has been working on seven new customer projects that focus on the conversion of flexible packaging to compostable formats. Six of these projects are for the North American market and one is in the UK.

 

In the first half of 2021, the business received a contractual commitment from a second US end customer for conversion to our biodegradable coffee filtration material. This has been referred to in various trading statements. Whilst initial implementation proceeded well and the end customer has been purchasing regularly in the past year, the subsequent acceleration of revenues has been constrained by various engineering matters within the customer's facilities. After some work, we understand that these engineering constraints have been addressed and we appear to be moving forward again, albeit not at the pace previously envisaged.

 

In the winter of 2021/22 Biome launched materials designed to allow tree shelters (plastic tubes around saplings) to be left in the forest after use to biodegrade in a benign manner. Last year, Biome announced the commencement of large-scale, UK-wide field testing and initial commercial sales by Suregreen Ltd (Biome's UK commercial partner) of biodegradable tree shelters using Biome's proprietary bioplastics materials. Based on extensive field testing of nearly 40,000 shelters, the Company is pleased that the real-world biodegradable product has performed exactly as expected.

 

Biome's scientists took samples of the biodegradable tree shelters this summer and tested them for mechanical properties and overall product performance. The product's tubes remain strong and resistant, degrading at the expected rate for their respective time periods. Comparing these lab-based field trial results against the Company's predictive models showed that the biodegradable tree shelters also performed as well as conventional counterparts. After this considerable piece of product performance monitoring work, the business is now preparing for a larger promotional campaign for the 2022/23 winter planting season in association with Suregreen Ltd (UK commercial partner).

 

The Bioplastics division will continue to benefit from the move to more sustainable materials. Future near-term growth is expected to be underpinned by several of the Division's customers which are planning product launches in H1 2023. Some of these launches are based on our new "home compostable" bio-based and biodegradable plastic grades ('BiomeHC') that are subject to the protection of a pending patent. The key "end-of-life" functionality of such materials is that they degrade much faster in conditions akin to a home compost bin rather than those materials designed to biodegrade in the controlled and higher temperature environments of industrial composting facilities. Biome's team has been working on this new range of materials for some three years and they are now ready for commercial service with a number of customers.

 

However, notwithstanding the various positive matters and initiatives described above, Biome Bioplastics is experiencing various customer launch delays related to raw material supply, logistics and uncertainty of end-consumer behaviour in the current economic climate. Some of these delays are significant and considered unlikely to resolve quickly, resulting in the Board's conclusion that Group revenues for the years ending 31 December 2022 and 2023 will be substantially below current market expectations.

 

Stanelco RF Technologies Division

Revenues for the first half of 2022 in RF Technologies were £0.4m (H1 2021: £0.3m), representing an increase of 24.8%.

 

The RF Technologies division has made good progress in securing business both in the latter half of 2021 and during H1 2022 across different industry sectors including food packaging and medical applications. In addition, we won a contract for two fibre-optic furnaces in late 2021 that are due for shipment in 2022. Like many businesses we have seen supply side challenges. This has affected deliveries of some critical long-lead time components and in particular, those items that contain semiconductors are on extended lead-times. Consequently, some of the orders that we had anticipated completing in H1 2022 have now or are now expected to ship in H2. Whilst this is frustrating, customers are understanding of such delays in the current environment.

 

Enquiry levels remain encouraging, and we continue to tender for contracts over a range of industry sectors and despite the requirement for new capacity in the fibre optic furnace market remaining modest there are pockets of activity for upgrades and spares that we are addressing. New order intake, during the year-to-date, has continued to be positive and an improving opportunity pipeline in sectors other than fibre optics gives us confidence that management's expectations for the RF Technologies division will be achieved.

 

With the medium to longer-term trend for the RF Technologies division improving, we have commenced recruitment to improve the range of internal technical resources required to achieve our growth targets whilst ensuring overhead expenditure remains controlled.

 

Outlook

The RF Technologies Division has been progressively overcoming the supply constraints that delayed customer deliveries during the first half of the year and the Board now expects that shipments in relation to all previously announced contracts will occur in H2 2022.

 

Biome Bioplastics' trading is seeing significantly increased risks and uncertainties surrounding the timing and scale of revenue opportunities as evidenced by the slower ramp of revenues from its second US customer. Whilst the Board is confident that new products to be launched in 2023 utilising Biome's Home Compostable materials will meet market approval, given the economic outlook generally and its impact on the Group's customers, the Board is taking a very cautious approach and considers that further delays and a scaling back of volumes are inevitable in the shorter term.

 

As a consequence of the challenging trading conditions described above, the Board now believes that Group revenues for the years ending 31 December 2023 and 2023 will be substantially below current market expectations with a consequential substantial impact on the Group's loss/profit before interest, taxation, depreciation, amortisation and share option charges.

Despite trading conditions deteriorating significantly, we believe we have sufficient working capital for the foreseeable future.

 

John Standen

Chairman

 

1 Loss before interest, taxation, depreciation and amortisation is an alternative profit measure as detailed in Note 7.

 

 

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the period ended 30 June 2022

 

Note

6 Months Ended

30 June

2022

6 Months Ended

30 June

2021

Year

Ended

31 December 2021

 

 

Unaudited

Unaudited

Audited

 

 

£'000

£'000

£'000

Revenue

5

2,428

2,589

5,734

Cost of goods sold

(1,562)

(1,731)

(3,794)

Gross Profit

866

858

1,940

Other operating income

203

110

364

Administrative expenses

(1,718)

(1,739)

(3,439)

Loss from operations

(649)

(771)

(1,135)

Finance and similar charges

(18)

(19)

(34)

Loss before taxation

(667)

(790)

(1,169)

Taxation

30

90

29

Total comprehensive loss for the period

(637)

(700)

(1,140)

 

Basic loss per share - pence

(17)p

(19)p

(30)p

Diluted loss per share - pence

(17)p

(19)p

(30)p

 

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2022

At30 June2022

At30 June2021

At31 December 2021

 

Unaudited

Unaudited

Audited

 

£'000

£'000

£'000

NON-CURRENT ASSETS

 

Other intangible assets

765

797

726

Property, plant and equipment

473

541

502

1,238

1,338

1,228

CURRENT ASSETS

 

Inventories

1,552

1,205

920

Trade and other receivables

861

1,228

1,377

Taxation receivable

109

90

79

Cash and cash equivalents

652

1,390

996

3,174

3,913

3,372

TOTAL ASSETS

4,412

5,251

4,600

CURRENT LIABILITIES

 

Trade and other payables

(1,761)

(1,587)

(1,298)

Lease liabilities

(47)

(43)

(40)

(1,808)

(1,630)

(1,338)

NON-CURRENT LIABILITIES

 

Lease liabilities

(340)

(381)

(361)

(340)

(381)

(361)

TOTAL LIABILITIES

(2,148)

(2,011)

(1,699)

NET ASSETS

2,264

3,240

2,901

EQUITY

 

Share capital

189

189

189

Share premium

2,282

2,282

2,282

Capital redemption reserve

4

4

4

Share options reserve

487

647

487

Translation reserve

(85)

(85)

(85)

Treasury shares reserve

(55)

(55)

(55)

Retained earnings

(558)

258

79

TOTAL EQUITY

2,264

3,240

2,901

 

The interim statements were approved by the Board on 21 September 2022.

Signed on behalf of the Board of Directors

Paul R Mines Rob Smith

Chief Executive Officer Chief Financial Officer

 

CONSOLIDATED STATEMENT OF CASH FLOWS

For the period ended 30 June 2022

At30 June2022

At30 June2021

At31 December2021

 

Unaudited

Unaudited

Audited

 

£'000

£'000

£'000

Loss after taxation:

(637)

(700)

(1,140)

Adjustments for: -

Taxation

(30)

(90)

(29)

Finance charges

18

19

34

Loss from operations

(649)

(771)

(1,135)

Adjustments for: -

Amortisation and impairment of intangible assets

174

169

353

Depreciation of property, plant and equipment

44

44

88

Share based payments - equity settled

-

38

48

Operating cash flows before movement in working capital

(431)

(520)

(646)

Increase in inventories

(632)

(459)

(174)

Decrease in receivables

516

211

13

Increase in payables

463

538

230

Cash utilised in operations

(84)

(230)

(577)

Taxation received

-

155

239

Interest paid

(18)

(19)

(34)

Net cashflow from operating activities

(102)

(94)

(372)

Investing activities

 

Investment in intangible assets

(213)

(145)

(258)

Purchase of property, plant and equipment

(7)

(10)

(8)

Net cash used in investing activities

(220)

(155)

(266)

Financing activities

 

Proceeds from issue of share capital

-

1

1

Repayment of obligations under leasing activities

(22)

(40)

(45)

Net cash from financing activities

(22)

(39)

(44)

Net decrease in cash and cash equivalents

(344)

(288)

(682)

Cash and cash equivalents at the beginning of the period

996

1,678

1,678

Cash and cash equivalents at the end of the period

652

1,390

996

 

 

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the period ended 30 June 2022

 

1. CORPORATE INFORMATION

The financial information for the period ended 30 June 2022 set out in this interim report does not constitute statutory accounts as defined in Section 434 of the Companies Act 2006. The Group's statutory financial statements for the year ended 31 December 2021 have been filed with the Registrar of Companies. The auditor's report on those financial statements was unqualified and did not contain statements under Section 498 of the Companies Act 2006. The interim results are unaudited. Biome Technologies plc is a public limited company incorporated and domiciled in England & Wales. The Company's ordinary shares are publicly traded on the AIM market of the London Stock Exchange.

 

2. BASIS OF PREPARATION

These interim consolidated financial statements (the interim financial statements) are for the six months ended 30 June 2022. They have been prepared in accordance with UK-adopted international accounting standards. They do not include all of the information required for full annual financial statements and should be read in conjunction with the consolidated financial statements of the Group for the year ended 31 December 2021.

 

These interim financial statements have been prepared in accordance with the accounting policies adopted in the last annual financial statements for the year to 31 December 2021.

 

The accounting policies have been applied consistently throughout the Group for the purposes of preparation of the interim financial statements.

 

3. BASIS OF CONSOLIDATION

The Group's interim financial statements consolidate the results of the Company and all of its subsidiary undertakings drawn up to 30 June 2022. As at 30 June 2022, the subsidiary undertakings were Biome Bioplastics Limited, Biome Bioplastics Inc., Stanelco RF Technologies Limited, Aquasol Limited and InGel Technologies Limited.

 

4. GOING CONCERN

The Directors have reviewed forecasts for the period to December 2023. These have been prepared with appropriate regard for the difficult current macroeconomic environment including the ongoing impact of Covid-19 "lockdowns" in China affecting supply chains and the markets and circumstances in which the Group operates. The forecasts included assumptions on exchange rates, supplier lead times and receipts from customers being broadly in line with agreed terms. The directors believe the assumptions to be reasonable but fundamental to the forecasts.

 

The Directors have considered the future growth of the Bioplastics Division, its need for continued investment in development resource and working capital, the steps they can take to improve the efficiency of the working capital deployed and the availability of future funding.

 

The model has assumed growth in the period from the Stanelco RF Division and the Directors have already taken steps to ensure resources meet current demand.

 

On the basis of the above, the Directors are satisfied that the Group has sufficient working capital to continue as a going concern for at least one year from the date of approval of these Interim Results.

5. SEGMENTAL INFORMATION

Revenue from external customers

For the period ended 30 June 2022

6 Months Ended30 June2022

6 Months Ended30 June2021

YearEnded31 December 2021

 

Unaudited

Unaudited

Audited

 

£'000

£'000

£'000

Biome Bioplastics Division

2,031

2,271

4,797

Stanelco RF Technologies Division

397

318

937

Total Revenue

2,428

2,589

5,734

 

6. LOSS PER SHARE

 

The calculation of basic earnings per share is based on the loss attributable to the equity holders of the parent for the period of £637,000 (H1 2021: loss of £700,000, FY 2021: loss of £1,140,000) and a weighted average of 3,755,930 ordinary shares in issue (H1 2021: 3,729,527, FY 2021: 3,742,655). The calculation uses the same weighted average number of shares under the basic and diluted basis in the current and comparative periods due to a loss being made.

 

7. ALTERNATIVE PROFIT MEASURE

 

The Group measures and reports on Earnings (Loss) Before Interest, Taxation, Amortisation and Depreciation (E(L)BITDA). The following table sets out the calculation of E(L)BITDA.

For the period ended 30 June 2022

6 Months Ended30 June2022

6 Months Ended30 June2021

YearEnded31 December 2021

 

Unaudited

Unaudited

Audited

 

£'000

£'000

£'000

Biome Bioplastics Division

2,031

2,271

4,797

Stanelco RF Technologies Division

397

318

937

Total Revenue

2,428

2,589

5,734

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR SEFFWFEESEIU
Date   Source Headline
15th Mar 20247:00 amRNSContract win for Stanelco RF Division
11th Mar 20241:59 pmRNSIssue of Convertible Loan Notes, PDMR Notification
15th Feb 20242:54 pmRNSContract win for RF Division
6th Feb 20247:00 amRNSTrading Update
13th Nov 20237:00 amRNSTrading Update
10th Oct 20234:32 pmRNSGrant of Options
27th Sep 20237:00 amRNSInterim Results
26th Jul 20237:00 amRNSTrading Update
30th Jun 20235:00 pmRNSTotal Voting Rights
22nd Jun 20237:00 amRNSContract win for Stanelco RF Division
31st May 20237:00 amRNSIssue of Equity, Director/PDMR Shareholding & TVR
25th May 20232:57 pmRNSAppointment of Non-Executive Director
25th May 202312:45 pmRNSResult of AGM
2nd May 20231:05 pmRNSDirector/PDMR Shareholding
27th Apr 20237:00 amRNSNotice of AGM and 2022 Annual Report
26th Apr 20237:01 amRNSTrading Update
26th Apr 20237:00 amRNSFinal Results 2022
18th Apr 202310:49 amRNSCompletion of CLN Fundraising
17th Apr 202311:30 amRNSResult of General Meeting
31st Mar 202311:14 amRNSProposed issue of Convertible Loan Notes
25th Jan 20237:00 amRNSTrading Update
16th Nov 20227:00 amRNSBiome receives £282k grant
10th Nov 202211:05 amRNSSecond Price Monitoring Extn
10th Nov 202211:00 amRNSPrice Monitoring Extension
10th Nov 20227:00 amRNSTrading Update
18th Oct 20229:28 amRNSHolding(s) in Company
22nd Sep 20224:41 pmRNSSecond Price Monitoring Extn
22nd Sep 20224:36 pmRNSPrice Monitoring Extension
22nd Sep 20222:05 pmRNSSecond Price Monitoring Extn
22nd Sep 20222:00 pmRNSPrice Monitoring Extension
22nd Sep 20229:05 amRNSSecond Price Monitoring Extn
22nd Sep 20229:00 amRNSPrice Monitoring Extension
22nd Sep 20227:00 amRNSInterim Results
5th Sep 20227:00 amRNSGrant funding from Innovate UK
2nd Aug 20228:59 amRNSTrading Update - Replacement
2nd Aug 20227:00 amRNSTrading Update
20th Apr 202212:01 pmRNSResult of Annual General Meeting
20th Apr 20227:00 amRNSTrading Update
30th Mar 20222:48 pmRNSDirector/PDMR Shareholding
30th Mar 20227:00 amRNSNotice of AGM and 2021 Annual Report
24th Mar 20227:00 amRNSFinal Results 2021
27th Jan 20227:00 amRNSTrading Update
4th Jan 202210:33 amRNSFurther substantial contract win for RF Division
16th Dec 20218:41 amRNSContract
17th Nov 20217:00 amRNSTrading Update
9th Nov 202111:12 amRNSHolding(s) in Company
25th Oct 20217:00 amRNSUpdate re biodegradable tree shelters
15th Sep 20217:00 amRNSInterim Results
30th Jul 20219:47 amRNSDirector/PDMR Shareholding
29th Jul 20217:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.